BeiGene to Collaborate With Novartis on Tislelizumab, Will Get $650 Million Upfront Payment
January 11 2021 - 6:08PM
Dow Jones News
By Josh Beckerman
BeiGene Ltd. will collaborate with Novartis AG on development of
BeiGene's anti-PD-1 antibody tislelizumab and will receive a $650
million upfront cash payment.
Beijing-based BeiGene, which focuses on cancer drugs, is
eligible to receive up to $1.55 billion in potential regulatory and
sales milestone payments, plus royalties on product sales.
The companies will jointly develop tislelizumab in various
markets including the U.S., European Union member countries, U.K.,
Russia, Japan, Canada and Mexico.
BeiGene American depositary receipts were up 1.8% after hours to
$283.99.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 11, 2021 17:53 ET (22:53 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
